Simplified Chinese
A delegation led by the Director-General of the National Agency of Drug and Food Control of the Republic of Indonesia paid a visit to Minhai.
Release date:
2018-08-08
Author:
Zhang Qian, Department of International Cooperation
Source:
Abstract
On August 7, 2018, a delegation of twelve, including Dr. Ir. Penny Kusumastuti Lukito, Director General of the National Agency of Drug and Food Control of the Republic of Indonesia (hereinafter referred to as “Indonesia’s NAFDAC”), Deputy Directors General Dra. Reri Indriani and Dra. Rr Maya Gustina Andarini, Director of the Drug Registration Division Togi Junice Hutadjulu, and Director of the Cooperation Division Diana ES Sutikno, paid a visit to Beijing Minhai Biotechnology Co., Ltd. Mr. Zheng Haifa, General Manager, and Mr. Liu Jiankai, Executive Deputy General Manager, along with other company leaders, extended a warm welcome to the Indonesian NAFDAC delegation on behalf of Minhai Biotechnology.
Company executives briefed the Indonesian Food and Drug Authority delegation on the company’s operations, including the development of novel vaccines, international collaborations, and overseas vaccine registration. The delegation then toured the company’s quality control and other departments.
Dr. Ir. Penny Kusumastuti Lukito, Head of Indonesia’s Food and Drug Authority, expressed full recognition of the company’s product R&D capabilities and overall strength, and stated that she hopes this visit will help facilitate and accelerate the entry of Minhai Biotech’s vaccine products into the Indonesian market, thereby fostering deeper cooperation between Minhai Biotech and Indonesia.
Minhai Biologics has expressed its interest in engaging in multi‑level, multi‑faceted cooperation with Indonesia, with the aim of further providing high‑quality, affordable vaccine products to the country and making a greater contribution to expanding China’s vaccine exports and advancing the development of China’s biopharmaceutical industry.

Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09